Business Context and Reporting Period
This Form 8-K, dated May 29, 2026, reports a material amendment to the Agreement and Plan of Merger between Lisata Therapeutics, Inc. (Lisata) and Kuva Labs Inc. (Parent), with Kuva Acquisition Corp. acting as the Purchaser. The filing details changes to the consideration structure and timeline for the proposed acquisition of Lisata.
Key Financial Metrics and Transaction Terms
The filing does not contain standard financial statements (revenue, profit, cash flow, or debt). Instead, it outlines the revised financial consideration for the merger:
- Revised Cash Consideration: Reduced from $5.00 per share to $4.00 per share in cash, net to the seller.
- Contingent Value Rights (CVRs): Each share receives one non-tradeable CVR with a potential aggregate payout of up to $3.00, structured as two milestones:
- First Milestone ($1.25): Triggered by completion of enrollment, enrollment of at least 90% of targets, or termination of the Phase 2a GBM study (LSTA1-GBM-2A). Payment due by December 15, 2026, or 45 days post-milestone.
- Second Milestone ($1.75): Triggered by the filing or formal acceptance of a New Drug Application (NDA) for certepetide (LSTA1) by the FDA or analogous body. Payment due 45 days post-milestone.
- Interest on Unpaid Milestones: If the First Milestone Payment is not made when due, unpaid amounts accrue interest at the least of 10% per annum, SOFR + 5%, or the maximum rate permitted by law.
Material Changes Versus Prior Period
Compared to the Original Merger Agreement dated March 6, 2026, the following material changes were implemented:
- Consideration Structure: The upfront cash offer was reduced by $1.00 per share ($5.00 to $4.00). The CVR structure was modified from a single $1.00 contingent payment to a two-tiered structure with a higher potential aggregate value ($3.00) tied to specific clinical and regulatory milestones.
- Tender Offer Commencement: The date for the commencement of the tender offer was extended from May 29, 2026, to June 1, 2026.
- Outside Date: The deadline for the transaction (Outside Date) was extended from July 1, 2026, to July 6, 2026.
Guidance, Outlook, Risks, and Contingencies
Outlook and Management Commentary: The Company and Parent have agreed to proceed with the amended terms, with the tender offer expected to commence on June 1, 2026. The filing emphasizes that the transaction is subject to closing conditions and the successful achievement of clinical milestones for CVR payouts.
Risks and Contingencies:
- Transaction Completion: Risks include the failure to commence the tender offer, failure to satisfy closing conditions, or termination of the Merger Agreement.
- CVR Payout Uncertainty: There is a risk that the clinical milestones (Phase 2a enrollment or NDA filing) may never be achieved, resulting in no CVR payments.
- Regulatory and Clinical Risks: Success depends on the efficacy and safety of the product candidate (certepetide/LSTA1) and regulatory agency actions.
- Legal and Financial Risks: Potential stockholder litigation, termination fees, and uncertainties regarding employee retention and business partner responses.
Important Facts for Investor Verification
- Verify the final terms of the tender offer in the upcoming Schedule TO and Schedule 14D-9 filings.
- Confirm the specific enrollment targets and protocol details for the LSTA1-GBM-2A Phase 2a study to assess the likelihood of the $1.25 CVR milestone.
- Monitor the regulatory status of certepetide (LSTA1) to evaluate the probability of the $1.75 NDA filing milestone.
- Review the full text of the Amendment (Exhibit 2.1) and CVR Agreement (Exhibit 10.1) for detailed conditions and definitions.
- Check for any competing offers or legal proceedings that could impact the transaction timeline or terms.